Harrow Health (HROW) Stock News

Harrow (NASDAQ:HROW) has secured exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio through a definitive agreement. The portfolio includes BYOOVIZ® (ranibizumab-nuna), a LUCENTIS biosimilar, and OPUVIZ™ (aflibercept-yszy), an EYLEA biosimilar, for treating retinal diseases.

The transition from current commercialization partner Biogen is expected to complete by end of 2025. This strategic acquisition targets a $9 billion U.S. market opportunity in retinal disease treatment, with current anti-VEGF therapies accounting for over $4.2 billion in annual Medicare Part B spending. The deal positions Harrow as a leading full-spectrum ophthalmic pharmaceuticals provider, aiming to improve treatment accessibility and affordability.

Samsung Bioepis has partnered with Harrow (NASDAQ: HROW) for the commercialization of two ophthalmology biosimilars in the United States. The agreement covers BYOOVIZ® (ranibizumab-nuna), the first FDA-approved ophthalmology biosimilar, and OPUVIZ™ (aflibercept-yszy).

The commercial license will become effective after Biogen's rights transition back to Samsung Bioepis by the end of 2025. BYOOVIZ, approved in September 2021, has been available since June 2022, while OPUVIZ received FDA approval in May 2024. Both biosimilars target conditions including Wet Age-Related Macular Degeneration, Macular Edema, and other eye disorders.

Harrow (HROW), a leading North American eyecare pharmaceutical company, has appointed Mike Biega as Vice President of Investor Relations and Communications. Biega, who brings over a decade of biotech investor relations experience, succeeds Jamie Webb, who is retiring. Webb will remain until August to ensure a smooth transition. Biega previously served as Sr. Director of Investor Relations at Sensei Biotherapeutics and was a Managing Director at Solebury Trout. He began his career at Summer Street Research Partners in healthcare equity sales. CEO Mark L. Baum expressed enthusiasm about Biega's appointment, highlighting his experience in strengthening investor engagement and communications strategy.

Harrow (HROW) has acquired exclusive U.S. commercial rights to BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05% from Formosa Pharmaceuticals. BYQLOVI, recently FDA-approved for post-operative inflammation and pain following ocular surgery, is the first new ophthalmic steroid in its class in over 15 years. The drug utilizes Formosa's APNT nanoparticle technology and demonstrated superior clinical outcomes. Key highlights include 77-85% pain relief by Day 4, 82-87% by Day 8, and exceptional inflammation clearance with 30-33% of patients showing zero cell counts by Day 8. BYQLOVI features a low 1.4% rate of elevated intraocular pressure and simplified twice-daily dosing for 14 days. Launch is expected in Q4 2025, targeting a market of over 7 million annual ophthalmic surgeries.

Harrow (NASDAQ: HROW), a leading North American eyecare pharmaceutical company, has announced its participation in two upcoming investor conferences in May 2025. The company will attend the B. Riley Securities 25th Annual Investor Conference in Marina del Rey, CA on May 21-22, featuring a fireside chat and one-on-one investor meetings. Additionally, management will participate in the Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis, MN on May 28, conducting one-on-one and small group investor meetings. Neither conference event will be webcast.

Harrow (HROW) reported its Q1 2025 financial results with total revenues of $47.8 million, marking a 38% increase from $34.6 million in Q1 2024. The company's key product VEVYE saw revenues rise to $21.5 million, up 35% from Q4 2024. Despite record cash flow from operations of $19.7 million, Harrow posted a GAAP net loss of $(17.8) million and Adjusted EBITDA of $(2.0) million. The company's VEVYE Access for All program, launched in mid-March, has shown promising results with prescription volumes and prescribers both increasing over 4X. Harrow maintains its 2025 revenue target of over $280 million and continues to seek strategic acquisitions in the ophthalmic pharmaceutical sector.

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close. The company will release its Q1 Letter to Stockholders on its website harrow.com. A conference call and live webcast to discuss the results is scheduled for May 9, 2025, at 8:00 a.m. Eastern Time. Investors can access the call via webcast through Harrow's website or by telephone after registering through the provided link. A replay of the webcast will be available on the company's website for one year.

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has partnered with Harrow (HROW) to launch an authorized generic version of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension). The ophthalmic medication is designed to treat and relieve bacterial eye infections. According to IQVIA data from January 2025, Maxitrol® and its generic equivalents generated annual sales of $20.8 million in the U.S. market.

Harrow (HROW) has expanded its VEVYE® Access for All (VAFA) program to include current Klarity-C Drops® patients, offering VEVYE at $59 per bottle. The expansion allows over 25,000 U.S. patients to convert their Klarity-C prescriptions to FDA-approved VEVYE, a cyclosporine ophthalmic solution 0.1% for dry eye disease treatment.

The program eliminates access barriers like prior authorization and reimbursement delays, while providing free home delivery and a money-back guarantee. Patients can choose between insurance coverage or Harrow's cash price. Klarity-C prescribers can transfer prescriptions through PhilRx's platform in under 5 minutes.